当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Use of multiple drains after mastectomy is associated with more patient discomfort and longer postoperative stay.

Use of multiple drains after mastectomy is associated with more patient discomfort and longer postoperative stay.

Abstract：

BACKGROUND:Seromas constitute a common complication following surgery for breast cancer, and closed drainage is used routinely to reduce its incidence. The aim of this study was to evaluate the influence of number of drains on patient discomfort, seroma formation, and hospital stay during the immediate postoperative period after mastectomy for breast cancer. PATIENTS AND METHODS:Based on a retrospective review of our clinical database, 110 consecutive patients from January 2004 through January 2006 who had undergone a mastectomy and axillary clearance for breast cancer were sent a simple postal questionnaire for collection of data. RESULTS:A total of 70 patients responded (all women; mean age, 69.4 +/- 11.4 years). Twenty-seven patients (38.57%) had 3 drains implanted unilaterally, 24 (34.28%) had 2, and 19 (27.14%) had 1 drain. They were divided into 2 groups: the first group with 1 drain (19 patients) and the other with 2 or 3 drains (51 patients). Median postoperative hospital stay was 2 days (range, 1-8 days); patients with 1 drain had a significantly shorter postoperative hospital stay (median, 2 days [range, 1-4 days] vs. 2 days [range, 1-8 days]; Mann-Whitney U test, P = .02). A total of 15 patients (21.43%) complained of a seroma. There was no difference in seroma rates between groups. Patients who had a single drain implanted had a significantly lower rate of discomfort (median, 2 [range, 1-5] vs. 3 [range, 1-7]; Mann-Whitney U test; P = .04). CONCLUSION:The number of drains used after a mastectomy for breast cancer did not significantly affect the rate or amount of seromas in this study, but the use of a single drain after mastectomy was significantly associated with less discomfort and shorter postoperative hospital stay.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Saratzis A,Soumian S,Willetts R,Rastall S,Stonelake PS

doi

10.3816/CBC.2009.n.041

subject

Has Abstract

pub_date

2009-11-01 00:00:00

pages

243-6

issue

4

eissn

1526-8209

issn

1938-0666

pii

H240221JG21M8414

journal_volume

9

pub_type

杂志文章

相关文献

Clinical Breast Cancer文献大全
  • The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08).

    abstract：BACKGROUND:Despite margin-negative breast-conserving surgery (BCS), phyllodes tumors (PT) of the breast show high local recurrence (LR) rates. In this study we aimed to assess the site and grade of LR to identify high-risk patients after initial treatment of malignant and borderline PT using BCS alone. PATIENTS AND ME...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2019.04.003

    authors： Choi N,Kim K,Shin KH,Kim Y,Moon HG,Park W,Choi DH,Kim SS,Ahn SD,Kim TH,Chun M,Kim YB,Kim S,Choi BO,Kim JH

    更新日期：2019-10-01 00:00:00

  • Outcome after ipsilateral breast tumor recurrence in patients with early-stage breast cancer treated with accelerated partial breast irradiation.

    abstract：PURPOSE:Limited outcomes exist in patients who develop an ipsilateral breast tumor recurrence (IBTR) after accelerated partial breast irradiation (APBI). The purpose of this study was to evaluate these outcomes and patterns of failure in our cohort of patients undergoing APBI. METHODS AND MATERIALS:A total of 534 pati...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2012.09.006

    authors： Shah C,Wilkinson JB,Jawad M,Wobb J,Berry S,Mitchell C,Wallace M,Vicini FA

    更新日期：2012-12-01 00:00:00

  • N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

    abstract：BACKGROUND:Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially in triple-negative breast cancer (TNBC). Cetuximab is a monoclonal antibody against EGFR with additive preclinica...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.08.002

    authors： Crozier JA,Advani PP,LaPlant B,Hobday T,Jaslowski AJ,Moreno-Aspitia A,Perez EA

    更新日期：2016-02-01 00:00:00

  • Improved Performance of Adjunctive Ultrasonography After Mammography Screening for Breast Cancer Among Chinese Females.

    abstract：INTRODUCTION:Until now, no studies have investigated whether women other than those with dense breasts are suitable for adjunctive ultrasonography after negative mammography, and investigated whether all women with negative mammography are suitable for adjunctive ultrasonography. METHODS:Based on the Multi-modality In...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.07.014

    authors： Dong H,Huang Y,Song F,Dai H,Liu P,Zhu Y,Wang P,Han J,Hao X,Chen K

    更新日期：2018-06-01 00:00:00

  • Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.

    abstract：INTRODUCTION:Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2018.12.018

    authors： Cacho-Díaz B,Spínola-Maroño H,Reynoso N,González-Aguilar A,Mohar-Betancourt A

    更新日期：2019-04-01 00:00:00

  • Prevalence of Ectopic Breast Tissue and Tumor: A 20-Year Single Center Experience.

    abstract：BACKGROUND:Ectopic breast tissue, which includes both supernumerary breast and aberrant breast tissue, is the most common congenital breast abnormality. Ectopic breast cancers are rare neoplasms that occur in 0.3% to 0.6% of all cases of breast cancer. PATIENTS AND METHODS:We retrospectively report, using a large seri...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.03.004

    authors： Famá F,Cicciú M,Sindoni A,Scarfó P,Pollicino A,Giacobbe G,Buccheri G,Taranto F,Palella J,Gioffré-Florio M

    更新日期：2016-08-01 00:00:00

  • Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.

    abstract：BACKGROUND:Intensive chemotherapy confers benefit to patients with high-risk early breast cancer (BC). We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy (ACAC) in older women with early BC. PATIENTS AND METHODS:Available data from women who received ACAC for BC in ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.12.001

    authors： Karavasilis V,Papadimitriou C,Gogas H,Kouvatseas G,Pentheroudakis G,Koutras A,Christodoulou C,Bafaloukos D,Samantas E,Pisanidis N,Papakostas P,Aravantinos G,Karanikiotis C,Kosmidis P,Pectasides D,Dimopoulos MA,Fountzilas

    更新日期：2016-08-01 00:00:00

  • Isolated Contralateral Axillary Lymph Node Involvement in Breast Cancer Represents a Locally Advanced Disease Not Distant Metastases.

    abstract：BACKGROUND:Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any oth...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.10.019

    authors： Chkheidze R,Sanders MAG,Haley B,Leitch AM,Sahoo S

    更新日期：2018-08-01 00:00:00

  • The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

    abstract：:Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...

    journal_title：Clinical breast cancer

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.3816/CBC.2002.n.020

    authors： Vogel VG,Costantino JP,Wickerham DL,Cronin WM,Wolmark N

    更新日期：2002-06-01 00:00:00

  • A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

    abstract：BACKGROUND:Three-drug regimens containing gemcitabine, an anthracycline, and a taxane produce response rates of 70%-90% in patients with metastatic breast cancer (MBC) although accompanied by considerable hematologic toxicity. We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docet...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CBC.2010.n.029

    authors： Yardley DA,Peacock NW,Dickson NR,White MB,Vázquez ER,Foust JT,Grapski R,Hendricks LK,Scott WL,Hainsworth JD

    更新日期：2010-06-01 00:00:00

  • Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.

    abstract：BACKGROUND:Elderly patients form a large proportion of patients with breast cancer but are underrepresented in clinical trials. We examined whether elderly patients experience more toxicity than younger patients within breast cancer clinical trials. MATERIALS AND METHODS:All breast cancer trials open from 1999 to 2012...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.09.002

    authors： Mariano C,Francl M,Pope J,Wong L,Lim HJ,Lohrisch C

    更新日期：2015-02-01 00:00:00

  • Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.

    abstract：BACKGROUND:This study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability. PATIENTS AND METHODS:All patients that received NPLD for MBC at 5 institutions were identi...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2013.10.011

    authors： Palmieri C,Misra V,Januszewski A,Yosef H,Ashford R,Keary I,Davidson N

    更新日期：2014-04-01 00:00:00

  • Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

    abstract：BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.06.001

    authors： Chung A,Choi M,Han BC,Bose S,Zhang X,Medina-Kauwe L,Sims J,Murali R,Taguiam M,Varda M,Schiff R,Giuliano A,Cui X

    更新日期：2015-12-01 00:00:00

  • Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.

    abstract：:Prostate adenocarcinoma can manifest as a fairly indolent tumor or as a very aggressive cancer with significant invasive and metastatic potential. Common metastatic sites include bone, liver, lymph nodes, and adrenal glands. Dermatologic manifestations are rare. We present a case of a man who presented with breast ski...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2010.n.013

    authors： Njiaju UO,Truica CI

    更新日期：2010-02-01 00:00:00

  • Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

    abstract：:Breast cancer is the most common type of cancer among women and the second leading cause of cancer death in the United States. Metastatic breast cancer is considered incurable, and treatment is aimed at palliating symptoms, achieving remission, and prolonging survival. Treatment options for metastatic disease vary bas...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2011.07.001

    authors： Sachdev JC,Jahanzeb M

    更新日期：2012-02-01 00:00:00

  • Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer.

    abstract：BACKGROUND:We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. MATERIALS AND METHODS:This study included the first 50 ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clbc.2011.09.002

    authors： Chadha M,Vongtama D,Friedmann P,Parris C,Boolbol SK,Woode R,Harrison LB

    更新日期：2012-02-01 00:00:00

  • Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

    abstract：BACKGROUND:Although brain metastases (BM) are associated with poor prognosis, patients with human epidermal growth factor receptor 2 (HER2) overexpressing (HER2+) breast cancer (BC) with BM who are treated with anti-HER2 therapy have a relatively longer survival after BM diagnosis compared with other subtypes and HER2+...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.12.009

    authors： Morikawa A,Wang R,Patil S,Diab A,Yang J,Hudis CA,McArthur HL,Beal K,Seidman AD

    更新日期：2018-10-01 00:00:00

  • Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.

    abstract：:Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2005.s.009

    authors： Jones SE,Pippen J

    更新日期：2005-04-01 00:00:00

  • Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy: A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer.

    abstract：BACKGROUND:Metastases to the brain occur in 10%-16% of patients with breast cancer, with incidence reportedly increasing. Historically, brain metastases (BM) have been treated with whole-brain radiation therapy (WBRT), but stereotactic radiosurgery (SRS) is an increasingly favored treatment option. In this study we use...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.11.001

    authors： Mainwaring W,Bowers J,Pham N,Pezzi T,Shukla M,Bonnen M,Ludwig M

    更新日期：2019-04-01 00:00:00

  • Taxanes and capecitabine in combination: rationale and clinical results.

    abstract：:The clinical utility of capecitabine as a single agent in metastatic breast cancer has been demonstrated with significant responses seen in women already treated with anthracyclines and taxanes. A phase II study in older women with metastatic breast cancer demonstrated capecitabine to be an effective front-line therap...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2002.n.004

    authors： Maher JF,Villalona-Calero MA

    更新日期：2002-01-01 00:00:00

  • A Guide to Prepectoral Breast Reconstruction: A New Dimension to Implant-based Breast Reconstruction.

    abstract：:Acellular dermal matrix has revolutionized implant-based breast reconstruction. Breast reconstruction has evolved from the traditional submuscular to the new prepectoral implant based (also known as muscle-sparing) reconstruction. The new technique is emerging as a highly popular surgery owing to its more minimal appr...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2016.11.009

    authors： Vidya R,Iqbal FM

    更新日期：2017-07-01 00:00:00

  • Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives.

    abstract：:[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a metabolic imaging modality that has increasing applications in oncology, neurology, and cardiology. Among the oncology applications, breast cancer is one of the most extensively studied diseases. FDG-PET has been performed for diagnosis, staging, and ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2003.s.016

    authors： Wu D,Gambhir SS

    更新日期：2003-04-01 00:00:00

  • Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer.

    abstract：INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.10.011

    authors： Murphy BL,Boughey JC,Hieken TJ

    更新日期：2017-07-01 00:00:00

  • Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancer.

    abstract：BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2008.n.014

    authors： Tchou J,Greshock J,Bergey MR,Sonnad SS,Sargen M,Weinstein S,Czerniecki BJ,Boraas M,Fraker DL,Rosato E,Fox K,Weber B,Solin LJ

    更新日期：2008-04-01 00:00:00

  • Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.

    abstract：:Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.s.006

    authors： Mamounas EP,Geyer CE Jr,Swain SM

    更新日期：2004-01-01 00:00:00

  • Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.

    abstract：:The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.01.002

    authors： Xu M,Yuan Y,Yan P,Jiang J,Ma P,Niu X,Ma S,Cai H,Yang K

    更新日期：2020-08-01 00:00:00

  • New horizons in treating metastatic disease.

    abstract：:The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2001.n.002

    authors： Cristofanilli M,Hortobagyi GN

    更新日期：2001-01-01 00:00:00

  • Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.

    abstract：:A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer I...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2001.n.008

    authors： Ross PJ,Powles TJ

    更新日期：2001-04-01 00:00:00

  • Spontaneous Rib Fractures After Breast Cancer Treatment Based on Bone Scans: Comparison Of Conventional Versus Hypofractionated Radiotherapy.

    abstract：BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.07.009

    authors： Kim DW,Kim JS,Kim K,Shin KH

    更新日期：2020-07-23 00:00:00

  • Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.

    abstract：PURPOSE:The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC). PATIENTS AND METHODS:Fifty-eight patients with IBC were treated between January 1994 and July 2002. Median age was 49 years. Thirty-eight patients had baseline...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2006.n.045

    authors： Gonzalez-Angulo AM,Guarneri V,Gong Y,Cristofanilli M,Morales-Vasquez F,Sneige N,Hortobagyi GN,Esteva FJ

    更新日期：2006-10-01 00:00:00